Does Blue Cross Blue Shield of Massachusetts Cover Semaglutide (Wegovy)?

What BCBS MA's Official Formulary Says About Wegovy

BCBS MA places Wegovy on Tier 3 or Tier 4 of most commercial formularies, which means the drug is covered but requires both prior authorization and, on many plans, step therapy. The exact tier depends on whether you have a fully-insured individual or small-group plan versus a self-insured employer plan administered by BCBS MA.

Fully-Insured vs. Self-Insured Plans

Fully-insured plans follow Massachusetts state insurance law and BCBS MA's standard drug formulary. Self-insured employer plans are governed by ERISA federal law, giving employers wide latitude to exclude or restrict anti-obesity medications entirely. This distinction matters because a colleague at a large Massachusetts employer may have no Wegovy benefit at all, while someone on a small-group ACA-compliant plan may have meaningful coverage.

Before starting a prior authorization, confirm with your HR department or BCBS MA member services (the number on the back of your card) whether your plan is fully-insured or self-insured. This single question saves weeks of wasted paperwork.

Massachusetts State Mandates and Anti-Obesity Drugs

Massachusetts does not currently mandate commercial insurers to cover anti-obesity medications the way it mandates coverage for certain diabetes drugs. The FDA approved Wegovy in June 2021 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. [1] State mandate status can change; the Massachusetts legislature has considered bills that would require obesity drug coverage, but none have been enacted as of mid-2025.

Clinical Criteria BCBS MA Uses to Approve Wegovy

Prior authorization approval for Wegovy under BCBS MA generally requires all of the following elements. Missing even one is the most common reason for denial.

BMI and Comorbidity Thresholds

The FDA label for Wegovy sets the minimum BMI at 30 kg/m², or 27 kg/m² with at least one weight-related condition. [1] BCBS MA's medical policy typically mirrors this threshold. Your prescribing clinician must document the current BMI measurement with a date, not just a historical number.

Qualifying comorbidities that support a BMI of 27 threshold include:

• Type 2 diabetes (HbA1c documented)
• Hypertension (blood pressure readings on file)
• Dyslipidemia (fasting lipid panel)
• Obstructive sleep apnea (formal sleep study or documented clinical diagnosis)
• Cardiovascular disease (applicable ICD-10 diagnosis)

Documented Lifestyle Intervention

Nearly all BCBS MA prior authorization forms for Wegovy ask for evidence of a structured diet and/or exercise program attempted for at least three to six months without sufficient weight loss. "Sufficient" in most policies means <5% total body weight reduction. Clinicians should document the specific intervention (e.g., caloric deficit diet, referral to a registered dietitian, 150 minutes per week of moderate activity per the 2018 Physical Activity Guidelines for Americans) [2] and the outcome.

The STEP-1 trial enrolled adults with a mean BMI of 37.9 kg/m² and showed that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% in the placebo group (P<0.001, N=1,961). [3] This clinical evidence is worth attaching to the prior authorization package, as it supports medical necessity.

Absence of Contraindications

BCBS MA reviewers check for documented contraindications before approving Wegovy. The FDA label lists a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) as absolute contraindications. [1] Active pancreatitis and pregnancy are also exclusions. Your prescriber must note the absence of these contraindications in the chart.

Step-by-Step Prior Authorization Process for BCBS MA

Getting Wegovy approved through BCBS MA involves a predictable sequence. Each step has a specific action item.

Step 1: Confirm Plan Coverage Before the Appointment

Log into your BCBS MA member portal or call member services. Search for "semaglutide" or "Wegovy" under drug benefits. Note the tier, any quantity limits, and whether a prior authorization is required. Print or screenshot this information.

Step 2: Your Clinician Submits the PA Form

BCBS MA accepts prior authorization requests electronically through CoverMyMeds or via fax. The standard Wegovy PA form asks for:

• Current height, weight, and BMI
• ICD-10 diagnosis codes (E66.9 for obesity, or relevant comorbidity codes)
• Duration and type of prior weight-loss interventions
• Absence of contraindications per the FDA label [1]
• Any prior anti-obesity medications tried and discontinued

Step 3: Medical Review (Standard 3-5 Business Days)

BCBS MA's pharmacy or medical review team evaluates the submission against their internal medical policy. Urgent reviews can be completed within 72 hours if a clinician documents that delay would seriously jeopardize the patient's health.

Step 4: Approval, Denial, or Peer-to-Peer Request

If approved, the authorization is typically valid for 12 months, after which re-authorization with documented weight-loss progress (usually at least 5% body weight reduction) is required.

If denied, the denial letter must state the specific clinical reason. Your clinician can request a peer-to-peer call with the BCBS MA reviewing physician within 14 calendar days of the denial. Peer-to-peer calls resolve roughly 30-50% of denials without a formal appeal.

What to Do If BCBS MA Denies Wegovy Coverage

Denial is not a final answer. Federal law and Massachusetts insurance regulations give you multiple appeal pathways.

Internal Appeal

You have the right to file a formal internal appeal within 180 days of receiving the denial letter under ACA regulations. [4] Submit the appeal with:

• A letter of medical necessity from your prescribing clinician
• Relevant clinical records (BMI documentation, comorbidity labs, prior diet program records)
• Published clinical evidence (e.g., the STEP-1 trial publication) [3]
• The SELECT trial (N=17,604) showing semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in patients with pre-existing cardiovascular disease and overweight or obesity, which may support medical necessity arguments for cardiovascular risk reduction [5]

The American Obesity Association's 2023 clinical practice guidelines note that "obesity is a chronic disease requiring long-term medical management," language that directly counters insurer arguments that weight-loss drugs are cosmetic or elective. [6]

External Independent Review

If the internal appeal is denied, Massachusetts law requires BCBS MA to offer an external independent review through the Massachusetts Division of Insurance. [7] An independent review organization (IRO) staffed by physicians who have no relationship with BCBS MA makes a binding decision, typically within 45 days for standard reviews or 72 hours for urgent cases.

State Complaints

Filing a complaint with the Massachusetts Division of Insurance (doi.mass.gov) alongside an external review creates a documented record that sometimes accelerates resolution.

How Much Does Wegovy Cost With and Without BCBS MA Coverage?

Cost varies significantly based on your specific plan design.

List Price and Typical Cost-Sharing

Novo Nordisk's current list price for Wegovy is approximately $1,349 per month for a four-pen carton. With BCBS MA Tier 3 coverage, a typical commercial plan copay ranges from $50 to $150 per month after the deductible is met. Some plans apply coinsurance (often 20-30%) rather than a flat copay, which at list price means $270 to $405 per month out of pocket even with coverage.

Novo Nordisk Savings Card

Commercially insured patients who are not covered by Medicare or Medicaid may qualify for Novo Nordisk's WeGovy savings card, which can reduce monthly cost to $0 for eligible patients for up to 24 months. This card does not work for Medicare Part D beneficiaries due to federal anti-kickback regulations. Eligibility and terms are subject to change; verify at WeGovy.com or through your pharmacist.

Medicare and Medicaid in Massachusetts

Medicare Part D historically excluded drugs approved solely for weight loss under the Social Security Act. The Inflation Reduction Act did not change this exclusion, though the TREAT and PREVENT Act has been introduced in Congress to amend it. MassHealth (Massachusetts Medicaid) coverage of Wegovy is limited and subject to the same prior authorization criteria described above.

Semaglutide for Type 2 Diabetes vs. Obesity: a Key Coverage Distinction

BCBS MA, like most insurers, distinguishes between semaglutide formulations by indication.

Ozempic (Semaglutide 0.5-2 mg) vs. Wegovy (Semaglutide 2.4 mg)

Ozempic is FDA-approved for type 2 diabetes management and is on most formularies as a diabetes drug with more favorable prior authorization criteria. [8] Wegovy carries the obesity indication. Some clinicians and patients attempt to use Ozempic off-label for weight loss, but BCBS MA may deny this if the patient does not have a type 2 diabetes diagnosis, and the IRS and CMS have signaled scrutiny of off-label GLP-1 prescribing patterns.

Rybelsus (oral semaglutide 7-14 mg) is also FDA-approved only for type 2 diabetes and faces similar formulary positioning. [9]

The SELECT Trial and Cardiovascular Indication

In August 2023, the FDA approved an expanded Wegovy label to include reduction of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and a BMI of 27 or higher. [5] This second indication gives prescribers an additional ICD-10 axis for the prior authorization, potentially improving approval rates for patients who meet the cardiovascular criterion even if the obesity-only pathway has been difficult.

Documenting Medical Necessity: What Clinicians Should Include

The quality of prior authorization documentation is the single largest variable in approval outcomes.

Optimal Chart Documentation Before Submitting

A well-constructed prior authorization package includes a dated BMI measurement, fasting metabolic labs (lipid panel, HbA1c, fasting glucose), blood pressure readings, any polysomnography reports, a summary of dietary interventions with dates and outcomes, and a brief narrative connecting the patient's weight-related comorbidities to the proposed treatment. Attaching the STEP-1 [3] and SELECT [5] trial citations as supporting references strengthens the medical necessity argument.

Clinician Letter of Medical Necessity Template Language

The Obesity Medicine Association recommends that letters of medical necessity explicitly state that obesity is a chronic, relapsing neurobiological disease, not a lifestyle failure. [10] Language such as "this patient meets FDA-approved labeling criteria for semaglutide 2.4 mg, has exhausted lower-intensity interventions, and has documented comorbidities that increase cardiovascular and metabolic risk" tends to perform better in peer-to-peer calls than vague requests.

The HealthRX clinical team has developed a tiered documentation framework for GLP-1 prior authorizations that groups patients into three submission tracks based on primary indication axis: obesity-only (BMI ≥30), obesity-plus-comorbidity (BMI ≥27 with qualifying condition), and cardiovascular risk reduction (established CVD, BMI ≥27 per expanded SELECT label). Each track uses a distinct ICD-10 lead code and a corresponding evidence package, which internal review suggests reduces the rate of first-submission denials compared to single-axis submissions.

Alternatives If Wegovy Coverage Is Denied

If BCBS MA denies Wegovy and appeals are exhausted, several clinical alternatives may have better formulary positioning.

Tirzepatide (Zepbound)

Zepbound (tirzepatide 2.5-15 mg weekly) received FDA approval for chronic weight management in November 2023. [11] The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% for placebo. [12] BCBS MA formulary placement for Zepbound varies by plan, and some plans may have preferential tiering for one GLP-1/GIP agonist over another based on rebate negotiations. Ask your pharmacist to run a formulary check for both Wegovy and Zepbound simultaneously.

Phentermine-Topiramate ER (Qsymia)

Qsymia is a lower-cost, orally administered option with a different mechanism of action. The FDA approved it for chronic weight management in 2012. [13] It carries fewer cardiovascular outcome data than semaglutide but may be covered at a lower tier and with less restrictive prior authorization requirements on some BCBS MA plans.

Bupropion-Naltrexone ER (Contrave)

Contrave combines a dopamine/norepinephrine reuptake inhibitor with an opioid antagonist. The COR-I trial (N=1,742) showed 6.1% placebo-subtracted weight loss at 56 weeks. [14] It is available generically in some formulations and may be covered at a preferred tier.

Frequently Asked Questions